Wednesday, September 9, 2009

What price health care reform in the US?

Tonight, President Obama will address both houses of Congress on the subject of health care reform. Like all Presidents, Obama is forced to compromise to find a consensus. But having agreed to play 'hunt the consensus', he is looking increasingly boxed in.

One deal that has already been done, presumably to buy-off opposition, is one that doesn't allow government to negotiate drug prices in return for a promise from Big Pharma not to gouge the taxpayer. This is a repeat of the Bush deal in 2003 that allowed Medicare to pick up the tab for senior citizens' prescription drugs, which was supposed to hold down drug costs without arm-twisting, because Big Pharma was going to sell more drugs and therefore make more money.

Sadly, the evidence points to exactly the opposite: Medicare's drug costs ballooned.

Take the gloves off in negotiations with Big Pharma and force them to lower prices and *hey presto!* costs for Medicare drop! Impact on the deficit? Positively reduces it.

Of course, Big Pharma and their shills will say that prices in the US subsidize all the nationalized health services, and enable them in innovate new drugs. BUT when you look at the number of new drugs coming to market, look at the % of Big Pharma's portfolios due to come off-patent in the next decade, you see that they have been doing next to nothing about the problem, except buying one another to increase their patented portfolios. Great for share prices, lousy for the health of the world!

Big Pharma will ask what their incentive to develop new drug is, but then we look at their behavior when given tax-breaks and we find examples such as Glaxo-SmithKline, who after the UK government set up a 5% tax-break for R&D spending, actually CUT their R&D spending and using the tax-break to cover the shortfall.

As Chairman of Astra Zeneca, Sir Tom McKilrop claimed that they loose 80% market share to generics when drugs go off-patent, so they have to make all their money on patented drugs to pay for new drugs. However, what McKilrop didn't address is that since Astra Zeneca abandoned generic drug sales (not profitable enough!), they allowed generics manufacturers invade their products' markets.

If this all sounds familiar, then maybe it's because it is much the same tactic that the Detroit Trio (Ford, GM & Chrysler), adopted in the face of competition, ceding the small car market to foreign competitors because there wasn't enough money in comparison with trucks & SUVs. Having given up on that segment, they failed to invest in capturing buyers who would have graduated up to their more profitable products. Eventually, the foreign competitors graduated from their cheaper small products to larger, more profitable products, eating into Detroits' remaining profitable markets.

The same thing is happening in the pharmaceutical industry as former generics manufacturers invest their generics profits into new drug development, suddenly Big Pharma become just another group of players in a huge, global market.

We all know how well, Detroit's strategy worked out, so here's hoping Big Pharma swallows the medicine and gets back to making drugs, and drops making policy!